Convertibles Calendar: XenoPort to price $100 million; Performant Financial on tap

January 29

XENOPORT INC.:

• $100 million convertible senior notes

• $15 million greenshoe

• Maturity 2022

• Rule 144A

• Non-callable for life

• Takeover and dividend protection

• Credit Suisse Securities (USA) LLC as bookrunner

• Proceeds to continue to commercialize Horizant, for further clinical development, including its XP23829 product candidate, and for general corporate purposes

• Santa Clara, Calif.-based XenoPort is a biopharmaceutical company.

• Nasdaq listing: XNPT

PERFORMANT FINANCIAL CORP.:

• $80 million convertible senior notes

• Maturity 2020

• Concurrent $50 million offering of common stock

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Morgan Stanley & Co. LLC and SunTrust Robinson Humphrey Inc.

• Proceeds to complete the company’s acquisition of Premier Healthcare Exchange Inc., or if the acquisition is not completed, to repay debt under the company’s senior secured credit facility

• Livermore, Calif.-based provider of technology to help identify and recover delinquent or defaulted assets and improper payments

• Nasdaq listing: PFMT

On The Horizon

INOTEK PHARMACEUTICALS CORP.:

• Convertible senior notes

• Maturity 2019

• Concurrent initial public offering of common stock

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Cowen & Co. LLC, Piper Jaffray & Co., Canaccord Genuity Inc. and Nomura Securities International Inc.

• Proceeds to fund the continued development of its pharmaceutical candidates and for other general corporate purposes, including repayment of borrowings under and the termination of existing notes payable agreements

• Beverly, Mass.-based development-stage pharmaceutical company

• Proposed Nasdaq listing: ITEK

CARNIVAL GROUP INTERNATIONAL HOLDING LTD.:

• Unsecured senior convertible bonds

• Bookrunner Deutsche Bank AG, Hong Kong Branch

• Regulation S

• Concurrent equity swap with Deutsche Bank AG, London Branch as equity swap counterparty

• Proceeds to fund existing and new projects; entry into the equity swap; and for working capital and other general corporate purposes

• Bermuda-based investment holding company engaged in leisure and consumption businesses

• Hong Kong: 00996

PLATFORM SPECIALTY PRODUCTS CORP.:

• Convertible securities as part of a funding package of cash, convertibles, debt and equity

• Proceeds to fund $3.51 billion acquisition of Arysta LifeScience Ltd., a Tokyo-based provider of agrochemical and biological products

• Barclays, Credit Suisse Securities (USA) LLC, Nomura Securities International LLC and UBS AG acted as M&A advisers and have committed financing for the acquisition

• Anticipated closing in first quarter 2015

• Miami-based specialty chemicals company

• NYSE: PAH

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.